Abstract
Twinrix (GlaxoSmithKline Biologicals, Rixensart, Belgium) is the first combined vaccine to provide protection against both hepatitis A and B. This review presents a critical analysis of antibody responses stratified by age following vaccination with Twinrix in 264 adults aged above 40 years. A month after completion of a 0-, 1-, 6-month vaccination schedule with Twinrix, a good response was observed for both anti-HAV and anti-HBs serum antibodies, suggesting that is an effective vaccine in older adults.
MeSH terms
-
Adult
-
Age Factors
-
Aged
-
Clinical Trials as Topic
-
Comorbidity
-
Databases, Factual
-
Female
-
Hepatitis A Antibodies / biosynthesis
-
Hepatitis A Antibodies / blood
-
Hepatitis A Vaccines / immunology*
-
Hepatitis B Antibodies / biosynthesis
-
Hepatitis B Antibodies / blood
-
Hepatitis B Vaccines / immunology*
-
Humans
-
Immunization Schedule
-
Male
-
Middle Aged
-
Randomized Controlled Trials as Topic
-
Retrospective Studies
-
Vaccination
-
Vaccines, Combined / immunology*
Substances
-
Hepatitis A Antibodies
-
Hepatitis A Vaccines
-
Hepatitis B Antibodies
-
Hepatitis B Vaccines
-
Vaccines, Combined
-
twinrix